Tovorafenib

{
  "id": "MLC-T-ONC-008785",
  "term": "Tovorafenib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat children aged 6 months and older with low-grade glioma (a type of brain tumor) that has certain mutations (changes) in the BRAF gene. It is used in patients whose tumor came back or did not get better after treatment with other therapy. It is also being studied in the treatment of other types of cancer. Tovorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep tumor cells from growing. It is a type of kinase inhibitor. Also called Ojemda.",
    "An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival."
  ],
  "synonyms": [
    "Ojemda"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tovorafenib/"
}